Texas scientists discover how a hepatitis C protein promotes liver cancer

December 05, 2005

GALVESTON, Texas--Scientists at the University of Texas Medical Branch at Galveston (UTMB) have identified a key biochemical connection between the hepatitis C virus and liver cancer.

The molecular mechanism is similar to the one that links the human papilloma virus (HPV), the cause of genital warts, and cervical cancer, according to Dr. Stanley M. Lemon, the senior author of a paper on the discovery that will be published this week in the online early edition of the Proceedings of the National Academy of Sciences.

"What we've found is that one of the hepatitis C virus proteins targets a cell protein that is crucial for suppressing the development of tumors, interfering with its ability to control cell proliferation," Lemon said. "By knocking out this 'tumor suppressor' and promoting the proliferation of liver cells, this viral protein is setting up the liver for cancer."

According to the federal Centers for Disease Control and Prevention, about 85 percent of liver cancer cases in the United States occur in people infected by the hepatitis C virus. Approximately 200 million people worldwide suffer from chronic hepatitis C, which can persist in the body for decades after an initial infection, often causing so much liver damage that a transplant may be a patient's only chance for survival. The most effective treatment available, interferon therapy, works only about half the time and often causes debilitating side effects. Those who fail treatment are at risk for fatal cirrhosis or developing liver cancer.

Researchers have known for a long time that hepatitis C virus infection can lead to liver cancer. But how the virus goes about this has been unclear.

The UTMB group discovered that the tumor-suppressing retinoblastoma protein is present at markedly reduced levels in cells containing a hepatitis C virus "replicon," a large piece of hepatitis C genetic material that is able to reproduce itself in cultured cells and also able to produce proteins made by hepatitis C viruses. "The replicon experiments enabled us to identify a protein known as NS5B that attaches to the retinoblastoma protein, a critical tumor suppressor, and accelerates its breakdown," Lemon said. He continued: "The way NS5B docks with the retinoblastoma protein is biochemically almost identical to the way a protein made by human papilloma virus does so to produce similar cancer-promoting results. That's interesting, because the two viruses are so different --HPV is a DNA virus, while hepatitis C is composed of RNA."

Understanding just how hepatitis C infection leads to the development of cancer is of critical importance, Lemon said. With no one "silver bullet" cure for hepatitis C on the horizon, he explained, researchers must use new knowledge to maximize the effectiveness of various virus-fighting therapies now under development, managing the care of chronically infected patients in ways that will best help them avoid liver cancer.
-end-
For more information or to schedule an interview request a digital photo or arrange a taped or live television interview via UTMB's satellite services, please call the media hotline.

University of Texas Medical Branch at Galveston

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.